rBCG Overexpressing Type I Interferon PAMPs and DAMPs

Case ID:
Disclosure Date:
Unmet Need
Bladder cancer is a global disease and the ninth most common cancer worldwide. In the United States, 81,190 patients will be diagnosed with bladder cancer in 2018. The first-line treatment for early stage bladder cancer is the transurethral resection of bladder tumors, followed by intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, 50% of patients will not respond to BCG therapy and require additional chemotherapy. Consequently, a more potent BCG therapy would have great therapeutic potential.
Technology Overview
Type I interferons (IFNs) are potent activators of antitumor immunity. Johns Hopkins researchers have found that Mycobacterium tuberculosis evades the type I IFN response via CdnP, a bacterial phosphodiesterase. To enhance the potency of BCG, they have developed a recombinant BCG (rBCG) strain that does not express bacterial phosphodiesterases, preventing their inhibition of type I IFN production. This rBCG strain has also been designed to overexpress enzymes that lead to the production of cyclic dinucleotides (CDNs). CDNs act as pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) that enhance the type I IFN response.  
Stage of Development
The inventors are testing the efficacy of their invention in bladder cancer cell lines and animal models. 
Dey R.J. et al., Nature Chemical Biology. 2017 December; (13): 210-217.
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
RECOMBINANT BCG THERAPEUTIC INTERVENTIONS FOR CANCER PCT: Patent Cooperation Treaty PCT PCT/US2019/022341   3/14/2019     Pending
For Information, Contact:
Sonriza Ford
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum